What You Should Know:
– Leidos is committing $10M to a five-year collaboration with the University of Pittsburgh’s Computational Pathology and AI Center of Excellence (CPACE) to accelerate the development and use of artificial intelligence (AI) in detecting and managing diseases.
– The partnership aims to create AI-powered tools for quicker disease detection, including heart disease and cancer, reduce diagnostic turnaround times, and enable earlier, more effective care management.
AI Disease Detection
Leidos brings to the collaboration its experience operating the National Cancer Institute’s Frederick National Laboratory for Cancer Research for over 25 years, along with its two decades of experience applying AI to healthcare and other critical sectors.
The Leidos-University of Pittsburgh collaboration focuses on several key objectives:
- Establishing a World-Class Research Hub: The University of Pittsburgh will enhance CPACE by further developing its state-of-the-art Digital Pathology Research Center. These facilities will support pioneering research in digital pathology and AI-driven diagnostics.
- Developing Digital Healthcare Solutions: The collaboration will advance AI-powered technologies, reinforcing the University of Pittsburgh’s leadership in digital pathology and enabling Leidos to develop innovative solutions for digital health and diagnostics.
- Accelerating Global Impact: Leidos intends to leverage the collaboration to deploy AI-powered digital pathology solutions across public and private healthcare sectors, driving the commercialization of innovative healthcare technologies.
“Our investment is aimed at using the transformative power of artificial intelligence to speed detection, diagnosis and treatment of diseases that affect millions of people annually,” said Leidos CEO Tom Bell. “These efforts will also focus on developing future health care specialists, and expanding the care that’s available to underserved communities, including our veterans.”
